

Surgical Outcomes of Transperitoneal Para-Aortic Lymphadenectomy Compared With Extraperitoneal Approach in Gynecologic Cancers: A Systematic Review and Meta-Analysis

Kun-peng Li, Xian-zhong Deng and Tao Wu*

Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China

OPEN ACCESS

Edited by:

Vito Andrea Capozzi, University Hospital of Parma, Italy

frontiers

in Surgery

Reviewed by:

Luciano Monfardini, University of Parma, Italy Carmine Conte, Catholic University of the Sacred Heart, Italy

> *Correspondence: Tao Wu alhawking@163.com

Specialty section:

This article was submitted to Obstetrics and Gynecology, a section of the journal Frontiers in Surgery

Received: 18 September 2021 Accepted: 18 November 2021 Published: 21 December 2021

Citation:

Li K-p, Deng X-z and Wu T (2021) Surgical Outcomes of Transperitoneal Para-Aortic Lymphadenectomy Compared With Extraperitoneal Approach in Gynecologic Cancers: A Systematic Review and Meta-Analysis. Front. Surg. 8:779372. doi: 10.3389/fsurg.2021.779372 **Purpose:** The optimal surgical approach for para-aortic lymphadenectomy (PALND) in gynecologic cancers using minimally invasive surgery (laparoscopy or robotic-assisted) is controversial. This study summarizes the current evidence on the extraperitoneal (EP) approach and compares its perioperative, surgical outcomes, and complications to the transperitoneal (TP) approach in an updated meta-analysis.

Methods: We performed a systematic search in PubMed, Embase, Web of Science, Cochrane Library database for randomized controlled trials (RCTs) and non-RCTs that compare EP to TP for PALND. The main outcomes included surgical, perioperative outcomes, and complications. The weighted mean difference (WMD) and odds ratio (OR) were applied for the comparison of continuous and dichotomous variables with 95% Cls. Three RCTs and 10 non-RCTs trials, including 2,354 patients were identified and enrolled in the meta-analysis.

Results: A total of three RCTs and ten non-RCTs trials, including 2,354 patients were identified and enrolled in the meta-analysis. We reported similar results for EP and TP in terms of the hospital stay, estimated blood loss, blood transfusion, conversion to laparotomy, total operative time, and postoperative complications (Clavien grade ≥ 1 and Clavien grade ≥ 3). However, the PALND operative time (WMD -10.46 min, 95% Cl -19.04, -1.88; p = 0.02) and intraoperative complications (OR 0.40, 95% Cl 0.23, 0.69; p = 0.001) were less with EP. Also, more nodes were removed in EP compared with the TP (WMD 1.45, 95% Cl 0.05, 2.86; p = 0.04).

Conclusions: The EP approach did not show differences regarding surgical and perioperative parameters compared with the TP approach. However, the number of aortic nodes retrieved was higher. Furthermore, The PALND operative time and intraoperative complications were less in EP.

Keywords: extraperitoneal approach, transperitoneal approach, gynecologic cancers, systematic review, metaanalysis

1

INTRODUCTION

Para-aortic lymphadenectomy (PALND) is a routine method for staging or treatment of gynecological malignancies (1). In the cervical cancers and advanced vaginal cancers, PALND is to guide the fields of radiation and also for the therapeutic benefits (1, 2). In endometrial and adnexal cancer, PALND is also performed for therapeutic purposes (3). In other words, PALND is useful for tailoring the optimally therapeutic purposes of patients according to their stage, providing adjuvant treatment for patients with infiltrated lymph nodes, and eliminating recurrence risk (4).

In the past, PALND was systematically performed using laparotomy. However, extraperitoneal (EP) and transperitoneal (TP) laparoscopy have also been used to perform PALND in the last few decades (5, 6). Furthermore, some recent studies also reported that minimally invasive salvage lymphadenectomy is an effective therapeutic approach for the recurrent patients with gynecological cancer bearing lymph-node recurrence. Without affecting the prognosis of the cancer, salvage lymphadenectomy is beneficial for perioperative and postoperative outcomes (7, 8). Since the reports on the effectiveness and safety of the robotassisted PALND in gynecologic oncology were published (9, 10), minimally invasive surgery (laparoscopic surgery or robotassisted) has become popular among surgeons in the field of PALND (11). However, to date, the optimal surgical approach for PALND in the gynecologic cancers is still controversial. Notably, Prodromidou et al. compared the outcomes of the EP and TP in 608 patients who underwent laparoscopic lymphadenectomy and conducted a meta-analysis that demonstrated clinically equivalent results between EP and TP (12). However, the outcomes of this meta-analysis are incomplete. There is no meta-analysis comparing the overall complications, major complications, and conversion to laparotomy between EP and TP. Furthermore, the included studies are all retrospective with low quality and are not up to date. So, more studies comparing EP with TP should be added to the scientific literature including RCTs and robotic assisted.

Therefore, we conducted a state-of-the-art meta-analysis to integrate all the accumulated evidence to date.

METHODS

This systematic review and meta-analysis were conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (13).

Literature Search Strategy, Study Selection, and Data Collection

We conducted a comprehensive electronic literature search in July 2021 in PubMed, Embase, Web of Science, and Cochrane Library database. Intervention and patient-related search terms were combined to build the following search string: laparoscopic or robot-assisted or minimally invasive and lymphadenectomy or gynecologic cancers or gynecological malignancies and transperitoneal or extraperitoneal or retroperitoneal.

Inclusion criteria were defined using the PICOS approach. P (patients): All the patients underwent EP vs. TP for

staging or treating gynecological malignancies. The malignancies included cancer of the endometrium, ovary, vagina, and cervix; I (intervention): undergoing EP; C (comparator): TP was performed as a comparator; O (outcome): one or more of the following outcomes: perioperative outcomes, surgical outcomes, and complications; S (study type): a retrospective, prospective comparative studies or RCTs. Exclusion criteria: (1) non-comparative studies; (2) editorial comments, meeting abstracts, case reports, or letters to the editor; and (3) none of the defined outcome measures analysis.

A total of two independent reviewers extracted the data. The following data were extracted for each study: (1) General information related to the manuscript: first author, year of publication, and country. (2) Population characteristics: sample size, age, body mass index (BMI), cancer type, and surgical history. (3) Perioperative outcomes: hospital stay, total operative time, PALND operative time, estimated blood loss, and blood transfusion. (4) Surgical outcomes: aortic lymph nodes and conversion to laparotomy. (5) Intraoperative complications, postoperative major complications (defined as Clavien grade \geq 1), postoperative major complications (defined as Clavien grade \geq 3) (14). Any dispute was resolved by consensus or consultation with a third reviewer.

Assessment of Bias Risk

Among the studies, ROBINS-I was used to assess for bias risk in non-RCTs (15). (1) confounding, (2) selection of participants, (3) classification of exposures, (4) departures from intended exposures, (5) missing data, (6) measurement of outcomes, and (7) selection of the reported result. The quality of RCTs was evaluated according to the tool of Cochrane Collaboration (16). It includes random sequence generation, allocation concealment, blinding of participants, personnel and outcome assessment, incomplete outcome data, selective reporting, and other sources of bias.

Statistical Analysis

Meta-analyses were performed using weighted mean differences (WMD) for continuous measures, while odds ratios (ORs) were used for the dichotomous outcomes. The results were reported with 95% CIs. Meta-analyses of continuous variables were pooled using the inverse variance method and dichotomous variables were performed using the Mantel–Haenszel method. Heterogeneity across the studies was assessed using the I^2 statistic (17). Taking account of predictable substantial between-trial heterogeneity, a random-effect model was used to combine all summary data. Review Manager 5.4 software (Rvman 5.3, Copenhagen: the Nordic Cochrane Center, the Cochrane Collaboration, 2014) was used for results synthesis. p < 0.05 was considered as statistically significant.

Subgroup Analysis

We performed a subgroup analysis based on the different minimally invasive surgery for PALND: laparoscopy and robotic-assisted.

Sensitivity Analysis

The robustness of the estimates was assessed by sensitivity analyses according to sample size (excluding studies with $<\!60$

patients) and applied the leave-one-out method to exclude studies one at a time from the pooled effect. However, sensitivity analyses were not performed in comparing three or fewer studies.

Publication Bias

The visual interpretation of funnel plot asymmetry is inherently subjective, so we also conducted the Egger test. On the contrary, when the test power was lacking when 10 or fewer studies were included, we could not evaluate the publication bias (18, 19).

RESULTS

Study Characteristics

According to the literature search and the inclusion criteria, we included 2,354 patients in 13 studies (3 RCTs and 10 non-RCTs) for meta-analysis (20–32). The 10 non-RCTs were all the retrospective comparisons (**Figure 1**). **Table 1** summarizes the number and baseline characteristics of the included patients having their associated preoperative variables and each




TABLE 1 | Baseline characteristics.

Reference	Country	Age	э(у)	BMI (k	g/m2)	Pati	ents	Cancer	type (n)	Surgio histor		Surgical approach
		EP	TP	EP	ТР	EP	ТР	EP	ТР	EP	TP	_
Bebia et al. (20)	Spanish	63.6(11.3)	61.6(11.5)	28.9(6.7)	28.0(6.6)	68	62	Cervix 55 Ovary 13	Cervix 43 Ovary 19	38	36	Robotic
Bebia et al. (21)	Spanish	64.06(7.7)	65.4(9.85)	31.0(6.4)	30.8(6.6)	35	38	Cervix 32 Ovary 3	Cervix 36 Ovary 2	15	16	Laparoscopic
Díaz-Feijoo et al. (21)	Spain	63.7(10.2)	63.0(11.0)	29.6(6.6)	29.1(6.7)	103	100	Cervix 87 Ovary 16	Cervix 79 Ovary 21	31	33	Laparoscopic
Kerbage et al. (22)	France	<60:527 (n) ≥60:140 (n)	<60:145 (n) ≥60:49 (n)	<30:491 (n) ≥30:119 (n)	<30:161 (n) ≥30:22 (n)	681	198	Cervix 572 Endometrium 41 Ovary 54 Vagina 2	Cervix 104 Endometrium 41 Ovary 39	NA	NA	Robotic
Kerbage et al. (22)	France	<60:31 (n) ≥60:12 (n)	<60:87 (n) ≥60:44 (n)	<30:31 (n) ≥30:13 (n)	<30:115 (n) ≥30:12 (n)	44	135	Cervix 37 Endometrium 47	Cervix 78 Endometrium 35 Ovary 18	NA	NA	Laparoscopic
Salhi et al. (23)	France	52.9(12.5)	56.4(12.9)	25.2(5.5)	25.6(4.5)	69	74	Cervix 63 Endometrium 5 Ovary 1	Cervix 29 Endometrium 38 Ovary 7	40	31	Laparoscopic
Beytout et al. (24)	France	57(13.5)	56(14.5)	24.0(5.75)	23(5.5)	44	56	Cervix 27 Endometrium 14 Ovary 1 Vagina 2	Cervix 20 Endometrium 25 Ovary 11	NA	NA	Laparoscopic
Díaz-Feijoo et al. (25)	Spain	65(13)	65(12.75)	29.0(6.15)	26.4(5.06)	31	29	Cervix 26 Endometrium 5	Cervix 22 Endometrium 7	14	17	Laparoscopic
O'Hanlan et al. (26)	USA	58(11.5)	57(12.75)	26.0(5)	26(5.5)	79	36	Cervix 4 Endometrium 53 Ovary 20	Cervix 0 Endometrium 53 Ovary 20	NA	NA	Laparoscopic
Akladios et al. (27)	France	55.2(9.25)	53.3(14.75)	26.9(7.25)	23.5(4.75)	21	51	Cervix 16 Endometrium 3 Ovary 1	Cervix 22 Endometrium 20 Ovary 8	12	22	Laparoscopic
Naoura et al. (28)	France	56(14)	54(14)	26.0(6)	24.0(4)	67	62	Cervix 41 Endometrium 22 Ovary 1 Vagina 3	Cervix 22 Endometrium 29 Ovary 11	49	39	Laparoscopic
Pakish et al. (29)	USA	62(11)	61(17)	35.1(6.7)	28.4(9.08)	34	108	Endometrium 34	Endometrium 108	NA	NA	Laparoscopic
Morales et al. (30)	Spain	52.4(12.4)	60.5(12.9)	28.6(41)	25.1(3.9)	28	19	Cervix 19 Endometrium 6 Ovary 3	Cervix 9 Endometrium 7 Ovary 3	NA	NA	Laparoscopic
Lambaudie et al. (31)	France	49(11.3)	43.1(8.8)	27.4(5.16)	22(3.4)	15	24	Cervix 14 Ovary 1	Cervix 24	NA	NA	Laparoscopic
Fleming et al. (32)	USA	65(8.25)	61(8.5)	29.0(4.5)	29.0(6.5)	19	24	Endometrium 19	Endometrium 24	NA	NA	Laparoscopic

BMI, body mass index; EP, extraperitoneal; TP, transperitoneal; Mean (SD).

intervention (age, BMI, cancer type, and surgical history). The baseline characteristics of the BMI were not relatively equal in the three studies (the mean BMI was more in EP compared with TP in the three studies; p < 0.05) (24, 30, 31). However, the preoperative characteristics were comparable in other studies,

with similar age, BMI, surgical history observed in each of the included studies. The patients in the two studies were divided into four groups, depending on their treatment type: TP laparoscopy, EP laparoscopy, TP robotic laparoscopy, and robot-assisted EP laparoscopy (20, 22).

Reference	hospital stay (day)	oital (day)	Total o time	Total operative time (min)	PALND opera time (min)	PALND operative time (min)	Estimated b loss (ml)	Estimated blood loss (ml)	E trans	Blood transfusion (n)	Aortic lymph nodes (n)	lymph s (n)	Con lapa	Conversion to laparotomy (n)
	Ð	Ч	Е	đ	£	đ	₽	đ	8	ТР	Ð	ТР	£	đ
Bebia et al. (20)	3(0.5)	3(0.5)	282.5(25)	282.5(18.75)	90(11.5)	90(10.0)	150(56.25)	200(57.5)	AA	AN	14.5(2.5)	13(2.25)	ω	ŋ
Bebia et al. (21)	2(0.25)	2(0.5)	270(18.75)	261(15)	90(6.25)	90(11.88)	105(17.5)	100(32.5)	AN	AA	13(1.75)	10(3)	F	-
Díaz-Feijoo et al. (21)	3(1.48)	3(1.48)	275(70.37)	270(44.4)	90(35.6)	90(37.0)	150(107.41)	110(111.1)	AN	AN	14(6.67)	12(7.41)	0	9
Kerbage et al. (22)	3(10)	3(5.75)	207.1(73.4)	214.6(88.3)	NA	NA	NA	NA	AN	AN	18(13)	14(12.5)	AN	AN
Kerbage et al. (22)	3(3.75)	3(4.5)	220.2(63.9)	257.1(117.1)	AN	NA	115.8(134.5)	141.5(265.7)	AN	AA	20(11.75)	13(12.25)	AN	AN
Salhi et al. (23)	4.2(2.6)	5(2.3)	166(77.8)	220.8(74.6)	NA	NA	191.1(197.0)	130(172)	AN	AN	11.7(6.3)	12.9(7.2)	AN	AN
Beytout et al. (24)	2.93(1.6)	3.72(2)	NA	NA	94(44)	110(43)	NA	NA	AN	AN	12(6)	16(6.5)	AN	AN
Díaz-Feijoo et al. (25)	3(1.5)	3(15)	260(57.5)	255(60)	90(27.5)	90(28.75)	105(97.5)	100(248.75)	ო	-	12(9.25)	13(6.25)	N	-
O'Hanlan et al. (26)	1.4(1.25)	1.1(1)	240(66.25)	202(56)	NA	NA	NA	NA	AN	AN	14(7)	10(9.5)	-	e
Akladios et al. (27)	5.6(3)	7.7(9.5)	NA	NA	125.7(33.75)	200.2(81.25)	NA	NA	-	0	13(5.5)	17(8.25)	AN	NA
Naoura et al. (28)	3.2(2)	3.7(2)	NA	NA	108(62)	110(41)	NA	NA	ო	ო	12(6)	15(5)	ო	4
Pakish et al. (29)	AN	NA	NA	NA	NA	NA	NA	NA	-	7	10(4.5)	5(5.75)	AN	NA
Morales et al. (30)	4.6(3.18)	4.5(1.6)	173(51)	211(38)	NA	NA	NA	NA	AA	AN	15(5.9)	17.4(8.6)	AN	NA
Lambaudie et al. (31)	2.6(0.6)	3.1(1.6)	202.1(6.4)	163.7(6)	NA	NA	70.9(69.3)	154.6(171)	NA	NA	16.7(8)	13.3(7.3)	ΝA	NA
Fleming et al. (32)	1.4(1.25)	1(1)	190(30)	179(30)	NA	NA	100(993.76)	100(137.5)	AA	AN	9(6.75)	7(3.75)	AN	AN

TABLE 3	Complication.
---------	---------------

Reference	Intra	operative	(C	operative Clavien ade ≥1)	(C	operative lavien ade ≥3)
	EP	TP	EP	TP	EP	TP
Bebia et al. (20)	2	6	17	15	2	1
Bebia et al. (21)	0	1	2	11	0	0
Díaz-Feijoo et al. (21)	2	7	3	1	1	1
Kerbage et al. (22)	NA	NA	86	23	78	15
Kerbage 2020 (b)	NA	NA	7	6	6	5
Salhi et al. (23)	4	9	12	9	NA	NA
Beytout et al. (24)	2	6	4	15	NA	NA
Díaz-Feijoo et al. (25)	0	4	7	12	5	9
O'Hanlan et al. (26)	2	4	NA	NA	NA	NA
Akladios et al. (27)	0	3	5	16	2	1
Naoura et al. (28)	3	6	7	15	NA	NA
Pakish et al. (29)	1	6	14	51	NA	NA
Morales et al. (30)	2	0	NA	NA	NA	NA
Lambaudie et al. (31)	NA	NA	1	1	NA	NA
Fleming et al. (32)	1	1	3	3	NA	NA

Perioperative and surgical outcomes are summarized in **Table 2**. The complications are summarized in **Table 3**, which includes intraoperative complications, postoperative overall complications, and postoperative major complications.

Assessment of Quality

The three RCTs were not double-blinded, the level of evidence was low. So, the three RCT studies had an intermediate risk of bias (Figure 2). On the other hand, because the 10 non-RCTs conducted retrospective comparative analysis, the level of evidence was intermediate. Overall, the risk of bias was considered moderate in 10 studies (Table 4; the details are in the Supplementary Material).

OUTCOME ANALYSIS

Perioperative Outcomes

When we pooled the results from the seven studies, the EP group demonstrated less PALND operative time compared to TP (WMD -10.46 min, 95% CI -19.04, -1.88; p = 0.02) (20, 21, 24, 25, 27, 28, 30). However, the sensitivity analysis showed no significant differences with the removal of two studies (23, 26) (p = 0.16, p = 0.10). It shows that the estimates were not robust. Pooled analysis in nine studies showed no significant differences in the total operative time (p = 0.78) (6, 9, 21–24, 30–32). After we performed the leave-one-out test eliminated studies with <60 patients and performed the leave-one-out test, the statistical significance did not change in the terms of total operative time (**Figure 3**).

There is no statistical significance in the hospital stay between EP and TP (twelve studies (p = 0.42) (20–28, 30–32). Pooled analysis in six studies showed no significant differences in estimated blood loss (p = 0.78) (20–25, 31, 32).

TABLE 2 | Perioperative and surgical outcomes

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	ncomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias	
Bebia 2021	•	•			?	?	•	
Díaz-Feijoo 2016	?	•	•	•	?	?	•	
Díaz-Feijoo 2021	•	•			?	?	•	
FIGURE 2 Risk of bias assessment [randomized contro	ol trials (RCTs)]							

In addition, pooling results from four studies (25, 27–29) no significant differences were found in blood transfusion (p = 0.52). Furthermore, there was no statistical significance in the


conversion to laparotomy between EP and TP (six studies; p = 1.00) (20, 21, 24–26, 28). Leave-one-out sensitivity analysis and excluding smaller studies also showed no significant differences

TARI F 4	The risk of hias	[nonrandomized	controlled trials	(RCTs)]-ROBINS-I.
	THE HAR OF DIAS	I I I I I I I I I I I I I I I I I I I	controlled thats	(1013)]-100110-1.

Bias domain	Kerbage et al. (22)	Salhi et al. (23)	Beytout et al. (24)	O'Hanlan et al. (26)	Akladios et al. (27)	Naoura et al. (28)	Pakish et al. (29)	Morales et al. (30)	Lambaudie et al. (31)	Fleming et al. (32)
Bias due to confounding	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate
Bias in selection of participants into the study	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low
Bias in classification of interventions	Low	Low	Low	Moderate	Low	Moderate	Low	Moderate	Low	Low
Bias due to deviations from intended interventions	Low	Low	Moderate	Low	Low	Low	Low	Low	Low	Low
Bias due to missing data	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low
Bias in measurement of outcomes	Low	Moderate	Moderate	Low	Moderate	Low	Moderate	Moderate	Low	Moderate
Bias in selection of the reported result	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate
Overall bias	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate

		EP			TP			Mean Difference	Mean Difference
Study or Subgroup	Mean		Total	Mean		Total	Weight	IV, Random, 95% Cl	IV. Random, 95% Cl
Akladios 2015	125.7		21	200.2		51		-74.50 [-101.06, -47.94]	
Bebia (a) 2021		11.25	68	90	10	62	17.8%	0.00 [-3.65, 3.65]	+
Bebia (b) 2021	90	6.25	35	90	11.86	38	17.6%	0.00 [-4.30, 4.30]	+
Beytout 2016	94	44	44	110	43	56	10.6%	-16.00 [-33.20, 1.20]	
Díaz-Feijoo 2016	90	27.5	31	90	28.75	29	12.2%	0.00 [-14.25, 14.25]	-+-
Díaz-Feijoo 2021	90	35.6	103	90	37	100	14.7%	0.00 [-9.99, 9.99]	-
Morales 2013	150	35	28	185	27	19	10.3%	-35.00 [-52.76, -17.24]	_ -
Naoura 2016	108	62	67	110	41	62	10.2%	-2.00 [-20.02, 16.02]	
Total (95% CI)			397			417	100.0%	-10.46 [-19.04, -1.88]	•
Heterogeneity: Tau ² =	: 104.30;	Chi ² =	46.61, 0	df = 7 (P	< 0.000	001); I ^z :	= 85%		-100 -50 0 50 100
Test for overall effect	Z = 2.39	(P = 0.)	02)						-100 -50 0 50 100 less in EP less in TP
3									
		EP			TP			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI
3.1.1 Robotic									
Bebia (b) 2021	270	18.75	35	261	15	38	12.3%	9.00 [1.17, 16.83]	-
Kerbage (b) 2020	220.2	63.9		257.1	117.1	60	6.1%	-36.90 [-72.15, -1.65]	
Subtotal (95% CI)			78			98	18.4%	-10.60 [-55.10, 33.90]	
Heterogeneity: Tau ² :	= 883.67;	Chi ² =	6.21, d	f=1 (P:	= 0.01);	l ² = 84	%		
Test for overall effect	Z=0.47	(P = 0.	64)						
3.1.2 Laparoscopic									
Bebia (a) 2021	282.5	25	68	282.5	18.75	62	12.3%	0.00 [-7.56, 7.56]	+
Díaz-Feijoo 2016	260	57.5	31	255	60	29	7.2%	5.00 [-24.78, 34.78]	
Díaz-Feijoo 2021	275	70.37	103	270	44.4	100	10.5%	5.00 [-11.14, 21.14]	
Fleming 2011	190	30	19	179	30	24	10.0%	11.00 [-7.06, 29.06]	+
	207.1	73.4	381	214.6	88.3	103	9.9%	-7.50 [-26.08, 11.08]	
Kerbage (a) 2020	202.1	64	15	163.7	6	24	6.6%	38.40 [5.92, 70.88]	
Kerbage (a) 2020 Lambaudie 2012	202.1		28	211	38	19	8.2%	-38.00 [-63.47, -12.53]	
	173	51		000	56	36	8.7%	38.00 [14.59, 61.41]	
Lambaudie 2012 Morales 2013 O'Hanlan 2015	173	66.25	79	202					
Lambaudie 2012 Morales 2013 O'Hanlan 2015 Salhi 2021	173		69	202	74.6	74		-54.80 [-79.82, -29.78]	
Lambaudie 2012 Morales 2013 O'Hanlan 2015 Salhi 2021 Subtotal (95% CI)	173 240 166	66.25 77.8	69 793	220.8		471	81.6%	-54.80 [-79.82, -29.78] - 0.66 [-15.62, 14.31]	←
Lambaudie 2012 Morales 2013 O'Hanlan 2015 Salhi 2021 Subtotal (95% CI) Heterogeneity: Tau ² :	173 240 166 = 398.33;	66.25 77.8 ; Chi ² =	69 793 45.00,	220.8		471	81.6%		
Lambaudie 2012 Morales 2013 O'Hanlan 2015 Salhi 2021 Subtotal (95% CI)	173 240 166 = 398.33;	66.25 77.8 ; Chi ² =	69 793 45.00,	220.8		471	81.6%		
Lambaudie 2012 Morales 2013 O'Hanlan 2015 Salhi 2021 Subtotal (95% CI) Heterogeneity: Tau ² :	173 240 166 = 398.33;	66.25 77.8 ; Chi ² =	69 793 45.00,	220.8		471 001); I ²	81.6%		
Lambaudie 2012 Morales 2013 O'Hanlan 2015 Salhi 2021 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect Total (95% CI) Heterogeneity: Tau ² :	173 240 166 = 398.33; : Z = 0.09 = 285.54;	66.25 77.8 Chi ² = (P = 0.	69 793 45.00, 93) 871 53.32,	220.8 df = 8 (F	9 < 0.00	471 001); I ² 569	81.6% = 82% 100.0%	-0.66 [-15.62, 14.31]	
Lambaudie 2012 Morales 2013 O'Hanlan 2015 Salhi 2021 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect Total (95% CI)	173 240 166 = 398.33; : Z = 0.09 = 285.54;	66.25 77.8 Chi ² = (P = 0.	69 793 45.00, 93) 871 53.32,	220.8 df = 8 (F	9 < 0.00	471 001); I ² 569	81.6% = 82% 100.0%	-0.66 [-15.62, 14.31]	-100 -50 0 50 100 less in EP less in TP

FIGURE 3 | Forest plots of para-aortic lymphadenectomy (PALND) operative time and total operative time for extraperitoneal (EP) vs. transperitoneal (TP). (A) PALND operative time; (B) total operative time. IV, inverse variance; DF, degrees of freedom.



between EP and TP in the terms of hospital stay, blood loss, blood transfusion, and conversion to laparotomy (**Figure 4**).

Aortic Lymph Nodes

During the aortic lymph nodes, fewer lymph nodes were removed in group TP compared with the group EP (WMD 1.45, 95% CI 0.05, 2.86; p = 0.04) (20–23, 25–32). However, no significant differences between the two groups were seen in the laparoscopic subgroup. Furthermore, after we eliminated studies with <60 patients and performed the leave-one-out test, the statistical significance changed in the terms of lymph nodes. Therefore, it proved that the estimates were not robust and the heterogeneity was high. We would discuss this further in the discussion section (**Figure 5**).

Complications

The intraoperative complication rates were 3.17 % (19 out of 598 cases) for EP and 7.74 % (51 of 659 cases) for TP, respectively (20, 21, 23–30, 32). The pooled estimates of intraoperative complication were less in EP compared with TP (eleven studies; OR 0.40, 95% CI 0.23, 0.69; p = 0.001). However, no significant differences were found in the postoperative overall complications (Clavien grade ≥ 1) and postoperative major complications (Clavien grade ≥ 3) (p = 0.24; p = 0.51). Furthermore, after we eliminated studies with <60 patients and performed the leave-one-out test, the statistical significance did not change in the terms of intraoperative, overall, and major

complications. However, in terms of postoperative complications about lymphocele, TA was associated with fewer complications compared with EP (OR 4.12, 95% CI 1.74, 9.75; p = 0.001) (**Figure 6**).

Heterogeneity

Most of the outcomes had moderate-to-low heterogeneity. High heterogeneity was found in the aortic lymph nodes, operative time, and blood loss. However, this is not surprised given the economic and cultural differences in the healthcare institutions worldwide publishing their data on EA and TA.

Publication Bias Assessment


Funnel plots are given in **Figure 7**. The results of Egger tests showed no evidence for the publication bias for hospital stay (p = 0.62), aortic lymph nodes (p = 0.70), overall complications (p = 0.78), and intraoperative complication (p = 0.54).

DISCUSSION

We report 11 comparative outcomes analyses of EP vs. TP. It includes 2,354 patients from 13 studies. Some conclusions drawn from the study are worthy of in-depth discussion.


Perioperative Outcomes

In the EP group, PALND operative time was less compared with the TP group. From a technical point of view, the main



Α	EP	TP		Odds Ratio		Odds Ratio
Study or Subgroup	Events Total E	vents Total		-H, Random, 95% Cl		M-H, Random, 95% Cl
Akladios 2015 Bebia (a) 2021	0 21 2 68	3 51 6 62	3.3% 11.2%	0.32 [0.02, 6.51] 0.28 [0.05, 1.46]		
Bebia (b) 2021	0 35	1 38		0.35 [0.01, 8.93]	_	
Beytout 2016	2 44	6 56	11.1%	0.40 [0.08, 2.07]		
Díaz-Feijoo 2016	0 31	4 29		0.09 [0.00, 1.75]		
Díaz-Feijoo 2021 Fleming 2011	2 103 1 19	7 100 1 24		0.26 [0.05, 1.30] 1.28 [0.07, 21.86]		
Morales 2013	2 28	0 19		3.68 [0.17, 81.03]		
Naoura 2016	3 67	4 62		0.68 [0.15, 3.17]		
O'Hanlan 2015	2 79	4 36		0.21 [0.04, 1.19]		
Pakish 2014 Salhi 2021	1 34 4 69	6 108 9 74		0.52 [0.06, 4.44] 0.44 [0.13, 1.52]		
00000 2021	4 05	5 14	20.170	0.44 [0.10, 1.02]		
Total (95% CI)	598		100.0%	0.40 [0.23, 0.69]		•
Total events	19	51	021112-000		_	
Heterogeneity: Tau ² = Test for overall effect			.92), 1-= 0%		0.005	0.1 1 10 200
		.,				less in EP less in TP
В						
	EP	TP		Odds Ratio		Odds Ratio
Study or Subgroup			Weight M	-H, Random, 95% Cl		M-H, Random, 95% Cl
8.1.1 Laparoscopic					_	
Bebia (b) 2021 Kerbage (b) 2020	2 35 7 45	11 38 6 135		0.15 [0.03, 0.73] 3.96 [1.26, 12.49]		
Subtotal (95% CI)	7 45 80	173		0.80 [0.03, 21.50]		
Total events	9	17				
Heterogeneity: Tau ² =			.0008); I ² = 9	1%		
Test for overall effect	Z = 0.13 (P = 0.90))				
8.1.2 Robotic						
Akladios 2015	5 21	16 51		0.68 [0.21, 2.19]		
Bebia (a) 2021	17 68	15 62		1.04 [0.47, 2.32]		
Beytout 2016 Díaz-Feijoo 2016	4 44 7 31	15 56 12 29		0.27 [0.08, 0.89] 0.41 [0.13, 1.27]		
Díaz-Feijoo 2010 Díaz-Feijoo 2021	3 103	1 100		2.97 [0.30, 29.04]		
Fleming 2011	3 19	3 24		1.31 [0.23, 7.38]		_
Kerbage (a) 2020	86 680	23 200		1.11 [0.68, 1.82]		
Lambaudie 2012 Naoura 2016	1 15 7 67	1 24 15 62	2.0% 9.1%	1.64 [0.09, 28.41] 0.37 [0.14, 0.97]		
Pakish 2014	14 34	51 108		0.78 [0.36, 1.71]		_ _
Salhi 2021	12 69	9 74	9.5%	1.52 [0.60, 3.87]		
Subtotal (95% CI)	1151	790	87.2%	0.81 [0.58, 1.15]		•
Total events Heterogeneity: Tau² :	159 - 0.07: Chiž - 12.69	161 df = 10 /P =	0 24) 12 - 21	96		
Test for overall effect			0.247,1 - 21	~		
Total (95% CI)	1231 168		100.0%	0.83 [0.54, 1.27]		
Total events Heterogeneity: Tau ² :		178), df = 12 (P =	0.02); I ² = 50	%		
Test for overall effect	Z = 0.88 (P = 0.38))			0.01	0.1 1 10 100 less in EP less in TP
Test for subaroup dif	/erences: Chi ² = 0.0	00. df = 1 (P =	0.99), I ² = 09	6		
С						
	50	TO		Odda Datio		Odda Datia
Study or Subgroup	EP Events Total E	TP Events Total	Weight M	Odds Ratio -H. Random, 95% Cl		Odds Ratio M-H, Random, 95% Cl
10.1.1 Robotic			Justifut In			
Bebia (b) 2021	0 68	0 62		Not estimable		
Kerbage (b) 2020	6 45	5 135		4.00 [1.16, 13.82]		
Subtotal (95% CI) Total events	113 6	197 5	20.2%	4.00 [1.16, 13.82]		
Heterogeneity: Not a	oplicable	5				
Test for overall effect)				
10.1.2 Laparoscopic Akladios 2015		1 51	7.1%	5.26 [0.45, 61.47]		
Bebia (a) 2021	2 21 2 68	1 51 1 62		1.85 [0.16, 20.90]		
Díaz-Feijoo 2016	5 31	9 29	20.2%	0.43 [0.12, 1.48]		
Díaz-Feijoo 2021	1 103	1 100		0.97 [0.06, 15.73]		
	78 680 903	15 200		1.60 [0.90, 2.84]		—
Kerbage (a) 2020		442 27	1 3.0 %	1.26 [0.63, 2.51]		
Kerbage (a) 2020 Subtotal (95% CI)	88		29); l² = 19%			
Kerbage (a) 2020 Subtotal (95% Cl) Total events Heterogeneity: Tau ² :						
Kerbage (a) 2020 Subtotal (95% CI) Total events	= 0.13; Chi ² = 4.94,					•
Kerbage (a) 2020 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect	= 0.13; Chi ² = 4.94, : Z = 0.65 (P = 0.51))	100.0%	1.58 10.78 3 101		-
Kerbage (a) 2020 Subtotal (95% Cl) Total events Heterogeneity: Tau ² :	= 0.13; Chi ² = 4.94,)	100.0%	1.58 [0.78, 3.19]		
Kerbage (a) 2020 Subtotal (95% CI) Total events Heterogeneity: Tau ² - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau ² -	= 0.13; Chi ² = 4.94, : Z = 0.65 (P = 0.51) 1016 94 = 0.24; Chi ² = 7.50,) 639 32 df = 5 (P = 0.1		1.58 [0.78, 3.19]	0.01	
Kerbage (a) 2020 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect	= 0.13; Chi ² = 4.94, : Z = 0.65 (P = 0.51) 1016 94 = 0.24; Chi ² = 7.50, : Z = 1.26 (P = 0.21)) 32 df= 5 (P = 0.1	9); I² = 33%		0.01	0.1 1 10 100 less in EP less in TP
Kerbage (a) 2020 Subtotal (95% CI) Total events Heterogeneity: Tau ² - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau ² -	= 0.13; Chi ² = 4.94, : Z = 0.65 (P = 0.51) 1016 94 = 0.24; Chi ² = 7.50, : Z = 1.26 (P = 0.21)) 32 df= 5 (P = 0.1	9); I² = 33%		0.01	
Kerbage (a) 2020 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect	= 0.13; Chi ² = 4.94, : Z = 0.65 (P = 0.51) 1016 94 = 0.24; Chi ² = 7.50, : Z = 1.26 (P = 0.21)) 32 df= 5 (P = 0.1	9); I² = 33%		0.01	
Kerbage (a) 2020 Subtotal (95% CI) Total events Heterogeneity. Tau ² = Test for overall effect Total events Heterogeneity. Tau ² = Test for overall effect Test for subaroup dif	= 0.13; Chi ² = 4.94, : Z = 0.65 (P = 0.51) 1016 94 = 0.24; Chi ² = 7.50, : Z = 1.26 (P = 0.21)) 32 df= 5 (P = 0.1	9); I² = 33%		L	
Kerbage (a) 2020 Subtotal (95% c)) Total events Heterogeneity: Tau ² = Test for overall effect Total (95% c)) Total events Heterogeneity: Tau ² = Test for overall effect Test for overall effect Test for overall effect Subdy or Subgroup	= 0.13; Chi ² = 4.94, Z = 0.65 (P = 0.51) 1016 94 = 0.24; Chi ² = 7.50, Z = 1.26 (P = 0.21) ferences: Chi ² = 2.9 EP Events Total E) 32 df = 5 (P = 0.*)) 55. df = 1 (P = TP Events Total	9); I ² = 33% 0.11). I ² = 60 <u>Weight M</u>	.7% Odds Ratio -H, Random, 95% CI	0.01	less in EP less in TP
Kerbage (a) 2020 Subtotal (95% C) Total events Heterogeneity, Tau ² Test for overall effect Total (95% C)) Total events Heterogeneity, Tau ² Test for overall effect Test for subaroup dif D Study or Subgroup Diaz-Feijoo 2016	$\begin{array}{c} = 0.13; \ \mathrm{Chi}^2 = 4.94, \\ Z = 0.85 \ (\mathrm{P} = 0.51) \\ & 1016 \\ 94 \\ = 0.24; \ \mathrm{Chi}^2 = 7.50, \\ Z = 1.26 \ (\mathrm{P} = 0.21) \\ \mathrm{ferences: \ Chi}^2 = 2.9 \\ \hline & \mathrm{EP} \\ \hline & 1 & 31 \end{array}$) 32 df = 5 (P = 0.1)) 55. df = 1 (P = TP <u>Events Total</u> 0 29	9); I ² = 33% 0.11). I ² = 60 <u>Weight M</u> 7.1%	0dds Ratio <u>-H, Random, 95% CI</u> 2.90 [0.11, 74.12]	0.01	less in EP less in TP Odds Ratio
Kerbage (a) 2020 Subtotal (95% C) Total events Heterogeneity, Tau ² : Test for overall effect Total (95% C) Total events Heterogeneity, Tau ² : Test for overall effect Test for suboroun dif D Study or Subgroup Díaz-Feijoo 2016 Kerbage (a) 2020	= 0.13; Chi ² = 4.94, Z = 0.65 (P = 0.51) 1016 94 = 0.24; Chi ² = 7.50, Z = 1.26 (P = 0.21) ferences: Chi ² = 2.9 EVENTS Total E 1 31 66 476) 32 df = 5 (P = 0.1) 55. df = 1 (P = TP TP Cvents Total 0 29 5 144	9); I [#] = 33% 0.11). I [#] = 60 <u>Weight M</u> 7.1% 85.9%	Odds Ratio <u>-H, Random, 95% CI</u> 2.90 [0.11, 74.12] 4.48 [1.77, 11.33]	0.01	less in EP less in TP Odds Ratio
Kerbage (a) 2020 Subtotal (95% C) Total events Heterogeneity, Tau ² Test for overall effect Total (95% C) Total events Heterogeneity, Tau ² Test for overall effect Test for subaroup dif D <u>Study or Subgroup</u> Díaz-Feijoo 2016 Kerbage (a) 2020 Morales 2013	= 0.13; Chi [™] = 4.94, Z = 0.65 (P = 0.51) 1016 94 = 0.24; Chi [™] = 7.50, Z = 1.26 (P = 0.21) Ferences: Chi [™] = 2.1 EP EVents Total E 1 31 66 476 1 28) 32 df = 5 (P = 0.1) 55. df = 1 (P = TP Cvents Total 0 29 5 144 0 19	9); I ² = 33% 0.11). I ² = 60 <u>Weight M</u> 7.1% 85.9% 7.0%	Odds Ratio <u>H. Random, 95% CI</u> 2.90 [0.11, 74.12] 4.48 [1.77, 11.33] 2.13 [0.08, 55.02]	0.01	less in EP less in TP Odds Ratio
Kerbage (a) 2020 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Testfor overall effect Total (95% CI) Total events Heterogeneity: Tau ² = Testfor overall effect Testfor subbroup df D <u>Study or Subproup</u> Díaz-Feijoo 2016 Kerbage (a) 2020 Morales 2013 Total (95% CI)	e 0.13; Chi ² = 4.94, Z = 0.65 (P = 0.51; 1016 94 = 0.24; Chi ² = 7.50, Z = 1.26 (P = 0.21; ferences: Chi ² = 2.9 EP Events Total E 1 31 66 476 1 28 535) 32 df = 5 (P = 0.1) 55. df = 1 (P = TP <u>Svents Total</u> 0 29 5 144 0 19 192	9); I [#] = 33% 0.11). I [#] = 60 <u>Weight M</u> 7.1% 85.9%	Odds Ratio <u>-H, Random, 95% CI</u> 2.90 [0.11, 74.12] 4.48 [1.77, 11.33]	0.01	less in EP less in TP Odds Ratio
Kerbage (a) 2020 Subtotal (95% C) Total events Heterogeneity, Tau ² Test for overall effect Total (95% CI) Total events Heterogeneity, Tau ² Test for overall effect Test for subaroup dif D <u>Study or Subaroup</u> Díaz-Feijoo 2016 Kerbage (a) 2020 Morales 2013 Total (95% CI) Total events	$ \begin{array}{c} {\rm e} \; 0.13; \; {\rm Ch}^{\rm P}=4.94, \\ {\rm ;} \; {\rm Z}=0.65\; ({\rm P}=0.51); \\ {\rm 1016} \\ {\rm 94} \\ {\rm e} \; 0.24; \; {\rm Ch}^{\rm P}=7.60, \\ {\rm Z}=1.26\; ({\rm P}=0.21); \\ {\rm Terences} : {\rm Ch}^{\rm P}=0.21; \\ {\rm Terences} : {\rm Ch}^{\rm P}=2.5; \\ {\rm Terences} : {\rm Total} \; {\rm E} \\ {\rm E} \\ {\rm I} {\rm 31} \\ {\rm 66} {\rm 476} \\ {\rm 1} {\rm 28} \\ {\rm 535} \\ {\rm 68} \end{array} $) 32 35 55 55 55 55 55 55 55 5 5 5	9); ² = 33% 0.11). ² = 60 <u>Weight M</u> 7.1% 85.9% 7.0% 100.0 %	Odds Ratio <u>H. Random, 95% CI</u> 2.90 [0.11, 74.12] 4.48 [1.77, 11.33] 2.13 [0.08, 55.02]		less in EP less in TP Odds Ratio
Kerbage (a) 2020 Subtotal (85% c)) Total events Heterogeneity: Tau ² = Test for overall effect Total (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect Test for subaroup dif D Study or Subgroup Diaz-Feijeo 2016 Kerbage (a) 2020 Morales 2013 Total (95% Cl)	= 0.13; Chi ² = 4.94, Z = 0.65 (P = 0.51) 1016 94 = 0.24; Chi ² = 7.50, Z = 1.26 (P = 0.21) ferences: Chi ² = 2.9 EP EVents Total E 1 31 66 476 1 28 535 68 = 0.00; Chi ² = 0.24,) 32 35 35 55 37 55 37 57 57 57 57 57 57 57 57 57 5	9); ² = 33% 0.11). ² = 60 <u>Weight M</u> 7.1% 85.9% 7.0% 100.0 %	Odds Ratio <u>H. Random, 95% CI</u> 2.90 [0.11, 74.12] 4.48 [1.77, 11.33] 2.13 [0.08, 55.02]	0.01	less in EP less in TP Odds Ratio

FIGURE 6 | Forest plots of complication outcomes for EP vs. TP. (A) Intraoperative complication; (B) postoperative overall complications (Clavien grade \geq 1); (C) postoperative major complications (Clavien grade \geq 3); (D) lymphocele). IV, inverse variance; DF, degrees of freedom.



advantage of the EP is the avoidance of intra-abdominal entry. It allowed for relatively rapid access to the vascular axes, especially the left aortic group of the lymph nodes until the level of the renal vein (33). Some studies also reported that the EP approach was associated with less PALND operative time over the TP approach (34, 35). However, after the removal of two studies, the sensitivity analysis showed no significant differences. On the other hand, because of the lack of study, we cannot perform a subgroup analysis based on the different surgical approaches for the PALND. Therefore, caution should be taken in evaluating the PALND operative time, no significant differences were found between EP and TP. The outcomes of this study about operative time largely align with those of Prodromidou et al. (12).

Results showed that there was no statistical significance in the hospital stay between EP and TP. However, surgeon and institutional volume are consistently shown to be important factors impacting the outcome of minimally invasive surgeries and PALND is no exception: a reduction in hospital stay and operative time with operative volume was demonstrated by Greco et al. (36). On the other hand, the cumulative analysis showed no significant difference between EP and TP in terms of estimated blood loss and blood transfusion. The technical difficulties of the EP approach include conversion to laparotomy due to greater difficulty in resolving intraoperative lesions, or accidental rupture of the peritoneum. However, in our study, the conversion to laparotomy rates were 5.85 % (25 out of 427 cases) for EP and 6.27 % (24 of 383 cases) for TP, respectively. Furthermore, previous studies have shown that conversion to laparotomy rates is similar between EP and TP about 6.0– 7.0% that are almost consistent with our study (27, 29). It is worth emphasizing that for patients with an ovarian malignancy or endometrial, conversion to laparotomy might be related to the need of performing other surgical procedures as part of the treatment of the disease, but not exclusively related to the procedure of PALND.

Aortic Lymph Nodes

More lymph nodes were removed in group EP compared with the group TP. However, no significant differences were found in the laparoscopic subgroup. First, the explanation for this inconsistency between studies is that in a large number of robotic TP procedures in an included study. The double docking was not achieved. Therefore, it prevented a more extensive lymph node dissection (22). In other words, the lymph node dissection rate might be influenced by the fact that the robotic procedures were performed with the older generation (37). Second, the mean BMI was more in EP compared with TP in the three studies (P < 0.05). Due to increased intra-abdominal adipose tissue, as the BMI increases, TP lymphadenectomy may not be sufficient to collect the lymph nodes of the renal blood vessels because of the poor visualization (38). There is no doubt that the difficulty of lymphadenectomy would be lower in the TP group because of the BMI. The EP approach could better enter the left aortic lymph nodes, especially into the challenging supra mesenteric lymph node group. There was no intestinal disturbance during the nodule dissection, and the left ureter was always visible (39). Therefore, EP seems advantageous compared with TP in the lymphadenectomy. As mentioned earlier, in obese patients, a study reported that in a review of 206 patients with endometrial cancer presenting with a BMI > 35 kg/m^2 , the median number of paraaortic nodes removed in TP was less compared with EP (40). Furthermore, a study had also shown that this technology can be safely and systematically applied to obese patients. It can perform thorough sampling and inspection, and the number of retrieved lymph nodes was greater in obese patients operated on using the EP approach compared with those undergoing TP (41).

Complications

The intraoperative complications were less in EP compared with TP. In terms of intraoperative complications, one advantage of the EP approach is the absence of bowel loops interposition in the surgical area and visualization of the ureters (42). Although, the finding was consistent with the previous meta-analysis results, the addition of six more well-powered studies comprising of 721 patients in this meta-analysis and the direct comparisons made in this study between EP and TP strengthen these findings. There is no statistical significance in the postoperative complications between EP and TP. However, TP was associated with less complications about lymphocele compared with EP, the first time that this has been demonstrated by meta-analysis. Postoperative lymphocele formation is the most reported complication associated with EP (30, 43). And marsupialization was a protective factor against lymphoceles. However, due to

the insufficient outcomes and systematic marsupialization at the end of the EP surgery have not been evaluated prospectively. We could not arrive at a completely reliable conclusion. On the other hand, the postoperative complications might have been influenced by difficulties in distinguishing specific complications associated with PALND from the remaining complications associated with surgery. There, we have to be cautious when evaluating the postoperative complications after EP and TP.

To avoid heterogeneity and bias, we have performed a subgroup analysis was performed based on the different minimally invasive surgery. However, the subgroup analysis was not performed for all outcomes because the data were lacking. Previous reports on the robotic surgery have demonstrated that the operative time, the hospital stay, and the rate of complications were similar between the two approaches (11, 44). But the sample size of those studies is small, it is difficult for us to arrive at a reliable conclusion. Therefore, in the future, we would require more studies on different minimally invasive surgery to verify this conclusion. On the other hand, previous reports have demonstrated that the robotic assistance could lead to a reduction in the hospital stay, blood loss and an increase in lymph node retrieval count, and complications compared with conventional laparoscopy in the obese patients (45). Moreover, robotic-enhanced precision of movements and visualization could lead to a shorter time required to retrieve each lymph node (46), improving the efficiency of the operation. However, no specific criteria were used to decide whether the robotic assistance or laparoscopy was used to perform the procedures, we need more evidence to prove the superiority of robotic assistance and reveal the patients most likely to benefit from the robotic assistance. At last, the perioperative, surgical outcomes and complications in minimally invasive surgeries were also affected by the expertise and learning curves of the surgeon. The surgical outcomes could be improved after the initial learning curve was complete (39, 47). Furthermore, the robot-assisted PALND has a steep learning curve similar to that for laparoscopic surgery (48, 49). Thus, those factors we should be taken into account. So, more high-level evidence was required to prove those findings.

There are some limitations of this study. First, only three studies were RCTs vs. 10 non-RCTs that might have resulted in unmeasurable confounding factors and selection bias. Furthermore, some of the included studies had small sample sizes. There is no doubt that it is a limitation of our study. Second, the baseline characteristics between the two groups were not entirely comparable. Although, most studies showed no statistically significant difference in the age and surgical history between each patient group, the baseline characteristics of the BMI were not relatively equal in the three studies. Third, the included studies did not report individual results for each cancer. It represents a potential confounding factor in evaluating oncology results. Last, due to the lack of reported outcome data in the qualified studies, some of the results we aimed to analyze could not be included in the meta-analysis.

There are no significant differences between EP and TP in terms of hospital stay, estimated blood loss, blood transfusion, conversion to laparotomy, total operative time, and postoperative complications. As expected, EP reported a lower rate of intraoperative complications as compared with TP, while more complications about lymphocele were found in the EP group. Furthermore, fewer lymph nodes were removed in group TP compared with the group EP. The main factors for choosing the approach are the habits of the patients, the location of the nodal disease, and importantly, the type of other procedures required to complete the surgery. Clinicians with advanced laparoscopic and/or robotics skills should be proficient in both techniques to suit the optimal approach of each patient. Furthermore, high-quality prospective randomized controlled trials should be conducted to compare the outcomes of different surgical approaches.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author.

REFERENCES

- Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. *Lancet.* (2010) 375:1165– 72. doi: 10.1016/S0140-6736(09)62002-X
- Mikami M. Role of lymphadenectomy for ovarian cancer. J Gynecol Oncol. (2014) 25:279–81. doi: 10.3802/jgo.2014.25.4.279
- AlHilli MM, Mariani A. The role of para-aortic lymphadenectomy in endometrial cancer. *Int J Clin Oncol.* (2013) 18:193– 9. doi: 10.1007/s10147-013-0528-7
- Marnitz S, Köhler C, Roth C, Füller J, Hinkelbein W, Schneider A. Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer? *Gynecol Oncol.* (2005) 99:536– 44. doi: 10.1016/j.ygyno.2005.07.005
- Montanari G, Di Donato N, Del Forno S, Benfenati A, Bertoldo V, Vincenzi C, et al. Laparoscopic management of early stage ovarian cancer: is it feasible, safe, and adequate? A retrospective study. *Eur J Gynaecol Oncol.* (2013) 34:415–8.
- Benedetti Panici P, Perniola G, Tomao F, Fischetti M, Savone D, Di Donato V, et al. An update of laparoscopy in cervical cancer staging: is it a useful procedure? *Oncology*. (2013) 85:160–5. doi: 10.1159/000351995
- Gallotta V, Bruno M, Conte C, Giudice MT, Davià F, Moro F, et al. Salvage lymphadenectomy in recurrent ovarian cancer patients: analysis of clinical outcome and BRCA1/2 gene mutational status. *Eur J Surg Oncol.* (2020) 46:1327–33. doi: 10.1016/j.ejso.2020.01.035
- Gallotta V, Giudice MT, Conte C, Sarandeses AV, D'Indinosante M, Federico A, et al. Minimally invasive salvage lymphadenectomy in gynecological cancer patients: a single institution series. *Eur J Surg Oncol.* (2018) 44:1568– 72. doi: 10.1016/j.ejso.2018.08.006
- Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, Skinner EN, et al. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. *Am J Obstet Gynecol.* (2008) 199:360.e1–9. doi: 10.1016/j.ajog.2008. 08.012

AUTHOR CONTRIBUTIONS

K-pL, X-zD, and TW worked on the protocol development, data collection and management, data analysis, and manuscript writing.

FUNDING

This study was supported by the City of Nanchong Strategic Cooperation with Local Universities Foundation of Technology (20SXQT0305). This work was supported by the Application and Basic Research Program of the Sichuan Science and Technology Department (2020YJ0185).

ACKNOWLEDGMENTS

We thank Ms Miao He for providing continuous encouragement to K-pL to pursue his career in medicine.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg. 2021.779372/full#supplementary-material

- Gallotta V, Federico A, Gaballa K. The role of robotic aortic lymphadenectomy in gynecological cancer: surgical and oncological outcome in a single institution experience. J Surg Oncol. (2019) 119:355–60. doi: 10.1002/jso.25335
- Díaz-Feijoo B, Gil-Ibáñez B, Pérez-Benavente A, Martínez-Gómez X, Colás E, Sánchez-Iglesias JL, et al. Comparison of robotic-assisted vs conventional laparoscopy for extraperitoneal paraaortic lymphadenectomy. *Gynecol Oncol.* (2014) 132:98–101. doi: 10.1016/j.ygyno.2013.11.004
- Prodromidou A, Machairas N, Spartalis E, Kostakis ID, Iavazzo C, Moris D, et al. Transperitoneal versus extraperitoneal laparoscopic lymphadenectomy for gynecological malignancies: a systematic review and meta-analysis. *Anticancer Res.* (2018) 38:4677–81. doi: 10.21873/anticanres.12773
- Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. (2015) 350:g7647. doi: 10.1136/bmj.g7647
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. (2004) 240:205–13. doi: 10.1097/01.sla.0000133083.54934.ae
- Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. (2016) 355:i4919. doi: 10.1136/bmj.i4919
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. (2011) 343:d5928. doi: 10.1136/bmj.d5928
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557
- Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. (2000) 53:1119–29. doi: 10.1016/S0895-4356(00)00242-0
- Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. *BMJ*. (2006) 333:597–600. doi: 10.1136/bmj.333.7568.597
- Bebia V, Gil-Moreno A, Hernández A, Gilabert-Estellés J, Franco-Camps S, de la Torre J, et al. Robot-assisted extraperitoneal para-aortic lymphadenectomy is associated with fewer surgical complications: a post hoc analysis of the

STELLA-2 randomized trial. *J Minim Invasive Gynecol.* (2021) 20:S1553–4650. doi: 10.1016/j.jmig.2021.05.009

- 21. Díaz-Feijoo B, Bebia V, Hernández A, Gilabert-Estalles J, Franco-Camps S. de la Torre J, et al. Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer. *Gynecol Oncol.* (2021) 160:83–90. doi: 10.1016/j.ygyno.2020.10.038
- Kerbage Y, Kakkos A, Kridelka F, Lambaudie E, Bats AS, Hébert T, et al. Lomboaortic lymphadenectomy in gynecological oncology: laparotomy, laparoscopy or robot-assisted laparoscopy? *Ann Surg Oncol.* (2020) 27:3891– 7. doi: 10.1245/s10434-020-08471-0
- Salhi Y, Gaillard T, Huchon C, Mezzadri M, Marchand E, Cornelis F, et al. Para-arortic lymhadenectomy and pelvic gynecological cancers: extraperitoneal or transperitoneal laparoscopy? *Gynecol Obstet Fertil Senol.* (2021) 49:838–43. doi: 10.1016/j.gofs.2021.05.004
- Beytout C, Laas E, Naoura I, Bendifallah S, Canlorbe G, Ballester M, et al. Single-port extra- and transperitoneal approach for paraaortic lymphadenectomy in gynecologic cancers: a propensity-adjusted analysis. *Ann Surg Oncol.* (2016) 23:952–8. doi: 10.1245/s10434-015-4874-8
- 25. Díaz-Feijoo B, Correa-Paris A, Pérez-Benavente A, Franco-Camps S, Sánchez-Iglesias JL, Cabrera S, et al. Prospective randomized trial comparing transperitoneal versus extraperitoneal laparoscopic aortic lymphadenectomy for surgical staging of endometrial and ovarian cancer: the STELLA trial. *Ann Surg Oncol.* (2016) 23:2966–74. doi: 10.1245/s10434-016-5229-9
- O'Hanlan KA, Sten MS, O'Holleran MS, Ford NN, Struck DM, McCutcheon SP. Infrarenal lymphadenectomy for gynecological malignancies: two laparoscopic approaches. *Gynecol Oncol.* (2015) 139:330–7. doi: 10.1016/j.ygyno.2015.09.019
- Akladios C, Ronzino V, Schrot-Sanyan S, Afors K, Fernandes R, Baldauf JJ, et al. Comparison between transperitoneal and extraperitoneal laparoscopic paraaortic lymphadenectomy in gynecologic malignancies. J Minim Invasive Gynecol. (2015) 22:268–74. doi: 10.1016/j.jmig.2014.10.011
- Naoura I, Laas E, Beytout C, Bendifallah S, Ballester M, Daraï E. A propensity score evaluation of single-port or multiport extraperitoneal paraaortic lymphadenectomy and the transperitoneal approach for gynecological cancers. *Bull Cancer*. (2016) 103:320–9. doi: 10.1016/j.bulcan.2016.01.009
- Pakish J, Soliman PT, Frumovitz M, Westin SN, Schmeler KM, Reis RD, et al. A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. *Gynecol Oncol.* (2014) 132:366–71. doi: 10.1016/j.ygyno.2013.12.019
- Morales S, Zapardiel I, Grabowski JP, Hernandez A, Diestro MD, Gonzalez-Benitez C, et al. Surgical outcome of extraperitoneal paraaortic lymph node dissections compared with transperitoneal approach in gynecologic cancer patients. *J Minim Invasive Gynecol.* (2013) 20:611– 5. doi: 10.1016/j.jmig.2013.03.009
- Lambaudie E, Narducci F, Leblanc E, Bannier M, Jauffret C, Cannone F, et al. Robotically assisted laparoscopy for paraaortic lymphadenectomy: technical description and results of an initial experience. *Surg Endosc.* (2012) 26:2430– 5. doi: 10.1007/s00464-012-2205-8
- Fleming ND, Axtell AE, Lentz SE. Operative and anesthetic outcomes in endometrial cancer staging via three minimally invasive methods. J Robot Surg. (2012) 6:337–44. doi: 10.1007/s11701-011-0319-y
- Vasilev SA, McGonigle KF. Extraperitoneal laparoscopic paraaortic lymph node dissection. *Gynecol Oncol.* (1996) 61:315– 20. doi: 10.1006/gyno.1996.0149
- Nagao S, Fujiwara K, Kagawa R, Kozuka Y, Oda T, Maehata K, et al. Feasibility of extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy. *Gynecol Oncol.* (2006) 103:732–5. doi: 10.1016/j.ygyno.2006.04.026
- 35. Benito V, Lubrano A, Arencibia O, Andújar M, Pinar B, Medina N, et al. Laparoscopic extraperitoneal para-aortic lymphadenectomy in the staging of locally advanced cervical cancer: is it a feasible procedure at a peripheral center? *Int J Gynecol Cancer.* (2012) 22:332–6. doi: 10.1097/IGC.0b013e31823c241b
- Greco F, Hoda MR, Rassweiler J, Fahlenkamp D, Neisius DA, Kutta A, et al. Laparoscopic adrenalectomy in urological centres - the experience of the German Laparoscopic Working Group. *BJU Int.* (2011) 108:1646– 51. doi: 10.1111/j.1464-410X.2010.10038.x

- Narducci F, Lambaudie E, Mautone D, Hudry D, Bresson L, Leblanc E. Extraperitoneal para-aortic lymphadenectomy by robotassisted laparoscopy in gynecologic oncology: preliminary experience and advantages and limitations. *Int J Gynecol Cancer*. (2015) 25:1494–502. doi: 10.1097/IGC.00000000000504
- Ponce J, Barahona M, Pla MJ, Rovira J, Garcia-Tejedor A, Gil-Ibanez B, et al. Robotic Transperitoneal infrarenal para-aortic lymphadenectomy with double docking: technique, learning curve, and perioperative outcomes. J Minim Invasive Gynecol. (2016) 23:622–7. doi: 10.1016/j.jmig.2016.02.005
- Occelli B, Narducci F, Lanvin D, LeBlanc E, Querleu D. Learning curves for transperitoneal laparoscopic and extraperitoneal endoscopic paraaortic lymphadenectomy. J Am Assoc Gynecol Laparosc. (2000) 7:51– 3. doi: 10.1016/S1074-3804(00)80009-2
- 40. Eisenhauer EL, Wypych KA, Mehrara BJ, Lawson C, Chi DS, Barakat RR, et al. Comparing surgical outcomes in obese women undergoing laparotomy, laparoscopy, or laparotomy with panniculectomy for the staging of uterine malignancy. *Ann Surg Oncol.* (2007) 14:2384–91. doi: 10.1245/s10434-007-9440-6
- 41. Dowdy SC, Aletti G, Cliby WA, Podratz KC, Mariani A. Extra-peritoneal laparoscopic para-aortic lymphadenectomy-a prospective cohort study of 293 patients with endometrial cancer. *Gynecol Oncol.* (2008) 111:418–24. doi: 10.1016/j.ygyno.2008.08.021
- Neveu ME, Bentivegna E, Gouy S. Extra-peritoneal laparoscopic para-aortic lymphadenectomy for staging of uterine cervix carcinoma. J Visc Surg. (2017) 154:115–22. doi: 10.1016/j.jviscsurg.2017.01.005
- Sonoda Y, Leblanc E, Querleu D, Castelain B, Papageorgiou TH, Lambaudie E, et al. Prospective evaluation of surgical staging of advanced cervical cancer via a laparoscopic extraperitoneal approach. *Gynecol Oncol.* (2003) 91:326– 31. doi: 10.1016/j.ygyno.2003.07.008
- 44. Geppert B, Persson J. Robotic infrarenal paraaortic and pelvic nodal staging for endometrial cancer: feasibility and lymphatic complications. *Acta Obstet Gynecol Scand.* (2015) 94:1074–81. doi: 10.1111/aogs.12712
- 45. Gehrig PA, Cantrell LA, Shafer A, Abaid LN, Mendivil A, Boggess JF. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman? *Gynecol Oncol.* (2008) 111:41–5. doi: 10.1016/j.ygyno.2008.06.030
- 46. Lee HJ, Lee YH, Chong GO, Hong DG, Lee YS. Robotic-assisted transperitoneal infrarenal para-aortic lymphadenectomy for gynecological malignancies: comparison with a laparoscopic approach. *Anticancer Res.* (2017) 37:7087–93. doi: 10.21873/anticanres.12182
- Patel A, Golan S, Razmaria A, Prasad S, Eggener S, Shalhav A. Early discharge after laparoscopic or robotic partial nephrectomy: care pathway evaluation. *BJU Int.* (2014) 113:592–7. doi: 10.1111/bju.12278
- Jacob A, Plaikner A, Schneider A, Favero G, Tozzi R, Mallmann P, et al. Comparison of surgical and pathological parameters after laparoscopic transperitoneal pelvic/para-aortic lymphadenectomies. *Int J Gynecol Cancer*. (2020) 30:1798–802. doi: 10.1136/ijgc-2020-001677
- Kim S, Ryu KJ, Min KJ, Lee S, Jung US, Hong JH, et al. Learning curve for sentinel lymph node mapping in gynecologic malignancies. J Surg Oncol. (2020) 121:599–604. doi: 10.1002/jso.25853

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Li, Deng and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.